HIMS & Hers Health FDA review of peptide therapies

What happened: On April 16, the FDA announced it would review wellness peptides, sparking a rally in Hims & Hers Health (HIMS) stock. Bank of America raised its price target on HIMS to $25, citing potential new revenue streams and repurposing of existing GLP-1 manufacturing capacity. The stock closed at $26.98, up 11.07%, with trading volume reaching 12.5 million shares. HHS Secretary Robert F. Kennedy Jr. also mentioned the FDA's consideration of removing restrictions on several peptides, further boosting HIMS shares.

Market impact: The FDA's review of wellness peptides positively impacted HIMS, a consumer-focused telehealth platform offering prescription and non-prescription health products. The company's stock price surged, benefiting investors and potentially attracting more capital. The development also signals a shift in regulatory sentiment towards wellness peptides, which could open new avenues for growth in the telehealth and wellness sectors.

What to watch next: Investors should closely monitor the FDA's review progress and any updates on the wellness peptides. Upcoming catalysts include HIMS' Q1 2023 earnings release on May 15, which may provide more insights into the company's growth prospects and potential revenue streams from wellness peptides. Additionally, any regulatory decisions or guidance from the FDA on peptide therapies will significantly influence HIMS' stock performance and the broader telehealth sector.